been observed that HLA-B27 may be present on the cell surface in noncanonical forms, which could lead to interactions with pathogenic killer cell immunoglobulinlike receptor-expressing T cells and enhanced expression of cytokines such as IL-17 (9) . The third hypothesis focuses on the role of peptide-driven immune responses underlying the chronic inflammation seen in AS. Recent genome-wide association studies in AS have identified a number of polymorphisms in genes that are central to antigen processing and presentation (10) , supporting this concept. While the nature of the arthritogenic peptides has remained undefined, a restricted T cell response profile would provide support for the notion of a peptide-specific host immune response in this disease (11) .
Previous studies have described T cell receptor b (TCRb) clones that may be associated with AS and reactive arthritis (12, 13) . Those studies used Sanger sequencing, resulting in a superficial view of the immune receptor repertoire. Recent studies have demonstrated the utility of TCRb repertoire sequencing for the elucidation of T cell response profiles and characterization of immune responses with unprecedented sensitivity (14) (15) (16) . In this approach, TCRb sequences are amplified and subjected to next-generation sequencing to assess all T cells present in the sample, including CD81 and CD41 T cells. As a result, all of the TCRb clonotypes in the sample are enumerated and quantified in a comprehensive analysis of the TCRb repertoire. In this study, we obtained the TCRb repertoire sequences of 234 samples from AS patients and 227 samples from controls, and we used 2 approaches to identify ASspecific TCRb sequences. We validated previously published AS-specific sequences, and we searched for novel sequences that are enriched among HLA-B27-positive AS patients as compared to controls.
MATERIALS AND METHODS
RNA and complementary DNA (cDNA) preparation. RNA and DNA were isolated using AllPrep DNA/RNA Mini and/or Micro kits, according to the manufacturer's instructions (Qiagen). RNA was reverse transcribed to cDNA using Vilo kits (Life Technologies).
TCRb amplification and sequencing. TCRb sequencing was performed using an immunoSEQ platform (Adaptive Biotechnologies Corporation). Briefly, cDNA was amplified using locus-specific primer sets for TCRb. This amplification reaction reproducibly amplifies all possible RNA transcripts found in the sample containing the rearranged TCRb locus regardless of which V segment and which common C region allele each rearranged molecule possessed, while appending the necessary sequences for cluster formation and sample indexing. First-stage primers were designed to allow for the amplification of all known alleles of the germline sequences, as previously described (14, 15, 17, 18) . In the second-stage polymerase chain reaction (PCR), primers on the C side anneal to the C segment with a 5 0 tail that contains the sequence primer and the P5 sequence used for cluster formation in an Illumina Genome Analyzer sequencer.
First-stage PCR was performed using a high-fidelity polymerase (AccuPrime; Life Technologies) for 16 cycles. Second-stage PCR was performed for 22 cycles on 1/100 of the amplification products from the first-stage PCR. Each sample contained a unique identifying tag. Samples were pooled and purified using the QIAquick PCR purification kit (Qiagen). Cluster formation and sequencing in both directions was performed using the Illumina HiSeq platform per the manufacturer's protocol.
Additional methods, including clonotype determination, identification of tested sequences and motifs, as well as enriched motifs and motif count distribution comparisons, description and analysis of the validation cohort of 587 healthy subjects, peripheral blood mononuclear cell (PBMC) collection, and T cell sorting, are described in the Supplementary Materials and Methods, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40028/abstract.
RESULTS
Characterization of the TCRb repertoire in AS patients and controls. We first sought to identify TCRb amino acid sequences that were significantly enriched among B27-positive AS patients as compared to control subjects. To do this, we initially characterized the TCRb repertoire in 191 B27-positive AS patients, 43 B27-negative AS patients, and 227 controls (174 lupus patients, 19 healthy controls, 24 patients with mechanical back pain and unknown HLA type, and 10 healthy B27-positive controls), as shown in Supplementary Table 1, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40028/abstract. Among the cohort of B27-positive AS patients, the mean 6 SD disease duration was 11.6 6 10.6 years, and the mean 6 SD modified Stoke Ankylosing Spondylitis Spine Score (19) was 13.5 6 19.6. The mean age of the AS patients was 33.2 years (range 18-61 years), and 78% of the patients were men and 22% were women. Thirty-five percent of the AS patients were receiving biologic agents (i.e., anti-tumor necrosis factor agents) at the time of blood collection.
Altogether, .77 million TCRb clonotype sequences were identified in the different samples. Supplementary Table 1 includes the average number of TCRb clonotypes in each case and control set. After deriving the amino acid sequence of each clonotype, we used 2 approaches to identify motifs that are specific to AS patients. First, we assessed whether previously published third complementaritydetermining region (CDR3) amino acid sequences were enriched in the B27-positive AS cohort as compared to controls. Second, we conducted a comprehensive search for TCRb amino acid sequences or motifs that are enriched in B27-positive AS patients as compared to control subjects. The study design is summarized in Figure 1A .
Identification of previously published TCRb sequences in AS samples. We assessed whether CDR3 sequences that were previously identified in patients with AS or reactive arthritis (12, 13) were enriched in the AS cohort as compared to controls. We identified a total of 50 different published CDR3 sequences, and we determined whether these published sequences were present in 128 B27-positive AS cases (published cases) and 193 controls (published controls). Motifs that were significantly associated with AS are shown in Table 1 . We considered a published case or published control sample to be positive for a particular sequence if it contained $1 clonotype that matched a published sequence. Only 40 of the 50 published sequences were observed in $1 published case or published control. Some of these 40 CDR3 amino acid sequences were highly related to each other, and were therefore combined into motifs (see Supplementary Materials and Methods, available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40028/abstract), resulting in 32 published motifs, 4 of which had .1 published sequence and 28 of which were singletons.
We then investigated whether any of these 32 published motifs was enriched in the published cases as compared to the published controls (Table 1 ). We found 6 published motifs that were significantly associated with the B27-positive AS cohort (false discovery rate [FDR] ,0.1). Of these, 3 were singleton sequences and 3 were motifs with multiple members. The frequencies of the motifs that were not found to be significantly enriched in the published cases are shown in Supplementary Table 2 , available on the Arthritis & Rheumatology § Related sequences were combined in a motif that was tested for enrichment in the cases compared to the controls. ankylosing spondylitis. † Test 1 cases versus test 1 controls, by false discovery rate-adjusted Fisher's exact test. ‡ Including training cases, test 1 cases, and test 2 B27-positive cases. § Related sequences were combined in a motif that was tested for enrichment in the cases compared to the controls. ¶ Related motifs from the discovered and published sets were combined into the cA and cB superfamilies. Identification of sequences enriched in the B27-positive AS cohort (training set). Next, we searched for TCRb amino acid sequences that are enriched in the TCRb repertoire of B27-positive AS patients as compared to controls. We selected 2 types of sequences: 1) sequences comprising a string of 10 amino acids in the target region, or "10-mers" and 2) sequences that contain a combination of 7 amino acids in the target region and particular V and J segments, or "7-mer combinations." Figure 1B includes a schematic illustration of the motif-finding technique, which is described in detail in the Supplementary Materials and Methods.
TCRb MOTIFS IN B27-POSITIVE ANKYLOSING SPONDYLITIS
For each of the 10-mers and 7-mer combinations, we enumerated all sequences that were observed. Each of these sequences was then analyzed to determine whether it was enriched in the HLA-B27-positive AS cohort as compared to the controls. We analyzed a subset of 64 of the 128 B27-positive AS patients described above (training cases) and 78 control samples from lupus patients (training controls) matched for the number of clonotypes identified (see Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40028/abstract). From this training set, we selected for further validation a total of 38 sequences (including 15 10-mers and 23 7-mer combinations) that were most markedly enriched in the cases versus the controls. Some of the 38 sequences selected were highly related, and they were thus coalesced into 27 discovered motifs (see Supplementary Materials and Methods). Six of these contained .1 member that differed by a single, conservative amino acid change.
Validation of motifs enriched in the B27-positive AS cohort (independent test set). We then assessed whether any of the 27 candidate discovered motifs identified in the training set were enriched in an independent test set that included the remaining 64 of the 128 B27-positive AS patients (test 1 cases) and 115 control patients (test 1 controls, including 96 lupus patients and 19 healthy controls) (see Supplementary Table 1) . We considered a case or control sample in the independent test set to be positive if $1 clonotype that matched a discovered motif from the training set was observed in that sample. As shown in Table  2 , 11 motifs were significantly enriched in the B27-positive AS patients as compared to controls (FDR , 0.1). Notably, all 6 of the motifs that contained .1 sequence were significant. The frequency of each of the significant published and discovered motifs was similar in the training and test sets (Figure 2 ). The motifs that did not reach significance comprised single clones, and 12 of the 16 nonsignificant motifs were observed at higher frequency in test 1 cases than in test 1 controls, suggesting that a fraction of these are likely to be enriched in the B27-positive AS patients (see Supplementary Table 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40028/abstract).
Overlap between published motifs and discovered TCRb repertoire motifs. We looked for overlap between the 6 positive published motifs (pA-pF) ( Table  1 ) and 11 positive discovered motifs (dA-dK) ( Table 2) . Two motifs from the published set (pA and pB) ( Table  1 ) overlapped with 2 of the discovered motifs (dA and dB) ( Table 2) , including the most strongly associated motif. The overlapping motif pairs were combined to make motif families cA and cB (Table 2) . Subsequent motif testing was performed on 3 groups of positive motifs. Group A consisted of 15 total motifs, including 4 published motifs (pC-pF), 9 discovered motifs (dCdK), and the 2 motif families (cA and cB). Group B included 6 total motifs, including 4 published motifs (pC-pF) and the 2 motif families (cA and cB). Group C consisted of 11 total motifs, including 9 discovered motifs (dC-dK) and the 2 motif families (cA and cB).
Correlation between the different motifs. We also looked at the presence of these 3 sets of motifs among the different subjects analyzed in this study. If these motifs were concentrated in a subset of the individuals, we would expect to observe a high correlation between them. Instead, we found little correlation between the detection of a specific positive motif in a sample and the detection of a second specific positive motif in the same sample, as evidenced by the lack of bright red or green squares, which would denote high correlation coefficients, in Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 40028/abstract.
Frequency of positive motifs in additional B27-positive AS patients, B27-negative AS patients, and patients with mechanical back pain. We then assessed the frequency of the 15 positive motifs in an additional 63 B27-positive AS patients (test 2 B27-positive cases) and 43 B27-negative AS patients (test 2 B27-negative cases), as well as in 24 patients with mechanical back pain (test 2 back pain controls) (see Supplementary Table 1 ). The frequency for each of the 15 positive motifs in the different cases and control cohorts is shown in Tables 1 and 2 , and in Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40028/abstract. As expected, the positive motifs were present in the test 2 back pain controls at levels comparable to those in the test 1 controls. Similarly, we found that the frequency of the positive motifs was similar between the test 1 cases and the test 2 B27-positive cases, further validating the positive motifs identified. Interestingly, the frequency of most of the positive motifs in the test 2 B27-negative cases was similar to that in the test 1 controls (Tables 1 and 2) , with the exception of one previously published motif, pE, which is similar in frequency between B27-negative and B27-positive AS patients.
Frequency of positive motifs in B27-positive healthy individuals. Since the control cohort was not HLA matched, we wanted to rule out the possibility that the positive motifs identified are B27 specific as opposed to AS specific. To address this, we first assessed an additional control cohort of 10 B27-positive healthy subjects (test 2 B27-positive healthy controls) and compared it to the set of 63 B27-positive AS patients (test 2 cases) (Supplementary Table 1 ). Neither of these cohorts was used in the selection and validation of the motifs, thus enabling an unbiased analysis of the frequency of the motifs. Because only 10 samples were available from B27-positive healthy subjects, we were unable to assess the statistical significance of the possible enrichment of each motif separately. Instead, we analyzed the total number of positive motifs that were present in each subject, and compared the distributions of positive motifs in the test 2 cases to each of 3 cohorts, corresponding to the 10 test 2 B27-positive healthy controls, the 43 B27-negative AS patients (test 2 B27-negative cases), and the 24 patients with mechanical back pain (test 2 back pain controls). We computed the frequency of each of the 3 groups of positive motifs described above ( Figure 3 ). As expected, for all 3 motif groups, there was a significantly higher number of motifs in the test 2 B27-positive cases than in the test 2 B27-negative cases and the test 2 back pain controls (Supplementary Table 4 ). Most importantly, for both group A (all 15 positive motifs) and group B (the published motif group), there was a significant difference between the frequency of the motifs in the test 2 cases and the healthy controls with the same HLA type (P 5 0.049 for group A and P 5 0.001 for group B), indicating that some of these motifs are specific to the disease and not just dependent on HLA type.
Validation of motifs in an independent set of HLA-B27-positive healthy controls. In order to expand the cohort of B27-positive healthy controls, we included previously reported TCRb repertoire sequencing data from an additional 587 HLA-typed healthy control subjects, including 42 B27-positive subjects, who we refer to herein as typed controls (20) . Although these data were collected using a TCRb repertoire sequencing approach similar to the one used for the data sets described above, there are important technical differences between the methods, including different primer sets, analysis algorithms, and the use of DNA (versus RNA) as the template for amplification (see Supplementary Materials and Methods).
We first sought to assess whether the 15 positive motifs (group A) had similar frequencies in the data sets generated using the 2 different technical approaches. In order to do this, we compared the frequency of the different motifs in the published control cohort to their frequency in the cohort of HLA-typed controls. Thirteen of the 15 motifs had a highly similar frequency in the 2 cohorts (Supplementary Table 5 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.
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FAHAM ET AL 1002/art.40028/abstract), and only 2 motifs (pE and dG) showed significantly different frequencies between these cohorts. The pE motif had a frequency of 25% in the typed controls, compared to 15% in the published controls. This difference may be due to the fact that a large number of the 193 subjects in the published controls test cohort were lupus patients, whereas the typed controls included 587 healthy subjects. Alternatively, it is possible that this is due to technical differences between the 2 methodologies, or the use of DNA versus RNA as the source material. Since this motif was present at a frequency of 8.3% in the back pain controls (n 5 24), we hypothesize that the observed difference in frequencies is more likely due to a technical difference rather than to the preponderance of lupus patients in the published control cohort. The second motif that showed a significant difference in frequency between the cohorts, dG, was present at a high frequency (46%) in the typed controls, compared to 5.7% in the published controls (or 9.6% after eliminating the 78 samples used in the training set). This frequency is much higher than that of all other motifs analyzed in any of the cases or control cohorts. Based on these observations, we eliminated from downstream analyses the 2 motifs that seemed to behave differently when using the 2 different methodologies.
Next, we focused on comparing the frequency of the 13 remaining motifs in the B27-positive cohorts. The frequency of these motifs in the initial 10 B27-positive healthy controls and the 42 B27-positive healthy subjects in the typed controls cohort was similar (Table 3) . We then compared the frequency of these motifs in the 42 B27-positive healthy subjects in the typed controls cohort to patients in the test 2 B27-positive cases cohort. The frequency of motifs cA and pC was significantly different between the 2 cohorts ( Table 3) . The motif for which there was the strongest evidence in this data set (cA) was observed in 62% of all B27-positive patients. If the other motif (pC) for which evidence of enrichment remains after considering the larger set of B27-positive controls is included in this analysis, an additional 9% of patients can be considered motif carriers. This observation provides additional evidence that some of the motifs identified are associated with AS and are not simply a result of the HLA genotype of the subjects.
Assessment of CD8 status of AS-specific clonotypes. In order to assess whether specific clonotypes were present in CD81 or CD41 T cells, we sorted PBMCs from a total of 12 samples from either B27-positive AS subjects, B27-negative AS subjects, or B27-positive healthy controls. For each of these samples, we sorted CD31/CD81 and CD31/CD82 (presumably CD31/CD41) cell populations. Next, the TCRb repertoire from RNA obtained from sorted and unsorted cells was amplified and sequenced as described in Materials and Methods.
For each of the clonotypes containing a positive motif in an individual, we assessed whether that clonotype was present in the CD31/CD81 or the CD31/CD82 cell populations. In all cases, a clonotype containing a positive motif in an individual was present exclusively in the CD31/ CD81 or the CD31/CD82 cell populations, unambiguously defining the T cell population of the clonotype as CD81 or presumptively CD41, respectively. We focused on the 2 motifs that were significantly different between the 2 cohorts. While the pC motif was not observed in any of the 12 subjects analyzed in this experiment, the cA motif was . Furthermore, the vast majority (11 of 12) of the clonotypes carrying the cA motif were observed in the sorted CD81 cells. In subject 5, we observed 2 clonotypes carrying the pA motif, one of which was observed in the CD82 (and thus presumably CD41) sort.
In addition, as shown in Supplementary Table 6 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40028/abstract, the majority of the 17 positive motifs are present in CD31/ CD81 T cells. Taken together, these data are consistent with the current biologic understanding that HLA-B27 presents antigenic peptides to CD81 T cells, thus providing further validation of the positive motifs.
Diversity of amino acid and nucleotide sequences for clonotypes of TCRb motifs. Our motif discovery search focused on identifying relatively short amino acid sequences that may not cover the full CDR3 sequence, as opposed to the full TCRb clonotype amino acid sequence. Therefore, for each of the 3 motifs with the strongest HLA-B27 association, we investigated the diversity of the clonotypes carrying these motifs in the different subjects. Specifically, we assessed the diversity of CDR3, full TCRb amino acid sequence, and nucleotide sequences carrying each of the 3 motifs with the strongest associations.
The discovered motif that demonstrated the strongest association (SVGLYSTDTQ) was observed in 130 samples in our study. While the CDR3 and full TCRb amino acid sequence were identical in all of these samples, the motif was represented by 59 different underlying nucleotide sequences. The CDR3 region of this motif is 13 amino acids long, and the N bases-diversity region-N bases (NDN) region of these clonotypes has a range of 9-13 nucleotides (median 11). Sequence diversity in the 13-nucleotide NDN region is illustrated in Supplementary Figure 4A The next most strongly associated discovered motif (TRBV19_TRBJ2-7_SSSRTNS) is a 7-mer combination motif which was found in 111 samples in our study. While the CDR3 and full amino acid sequence of TCRb were identical in all cases, the motif was represented by 54 different nucleotide sequences. The CDR3 region is 12 amino acids long, and the NDN region of these clonotypes has a range of 10-15 nucleotides (median 14). Sequence diversity in the 15-nucleotide NDN region is illustrated in Supplementary Figure 4B . The size of the D segment in the NDN region is ambiguous, since mapping to the D segment was not possible in 25 of 54 sequences.
The third most strongly associated discovered motif (SERTSGLYEQ) was observed in 85 cases, and its amino acid sequence diversity showed a very different pattern from the 2 described above. This motif was represented by 15 different amino acid sequences encoded by 63 different nucleotide sequences, with the CDR3 ranging from 12 to 13 amino acids.
In summary, in 2 of the 3 most strongly associated discovered motifs, the amino acid sequence over the full TCRb clonotype was identical, while in the third we observed a substantial diversity outside the motif.
DISCUSSION
While the association of MHC class I with AS has been recognized for 4 decades, the relationship of HLA- B27 to disease pathogenesis has remained obscure (2). Several mechanisms have been hypothesized to explain this association, but remain unproven (8) (9) (10) . Since the canonical role of MHC class I corresponds to the presentation of antigen to CD81 T cells, HLA-B27 as a restricting element in the immunopathogenesis of AS would predict the potential presence of shared TCRs among patients. Here we report the first systematic study of this question, and we provide evidence in support of the concept that some TCRs are enriched in HLA-B27-positive AS patients, consistent with an antigen-driven process orchestrated by HLA-B27. In this study, we used next-generation sequencing to identify TCRb amino acid motifs that are specific to B27-positive AS patients. We used 2 approaches to identify these motifs. We assessed previously published CDR3 motifs (12, 13) , and we undertook a motifdiscovery approach with strict training, test case, and control sets, resulting in the identification of 15 motifs that were enriched in B27-positive AS patients. Most importantly, we demonstrated that some of these motifs are present at a higher frequency in AS patients as compared to healthy individuals who are also B27 positive. This observation provides evidence for the hypothesis that specific antigens are involved in the pathogenesis of AS. Our finding is reminiscent of observations in carbamazepine-induced Stevens-Johnson syndrome and its related disease, toxic epidermal necrolysis, which have a strong association with HLA-B * 1502. By culturing carbamazepine-specific T cells from affected individuals, Ko et al (21) identified a predominant clonotype found among the vast majority of the patients with druginduced sensitivity, but which was found at a low frequency among the healthy subjects, and not found among tolerant control subjects.
One of the strengths of the present study resides in the comprehensive approach to motif discovery. A high rate of validation of the positive motifs was observed in the test sets, providing strong evidence of the authenticity of these motifs. Moreover, these studies were conducted using samples from a large number of cases and controls (191 B27-positive AS patients, 43 B27-negative AS patients, and 227 controls), affording confidence in the validity of the positive motifs.
While the large number of AS cases and controls is also a key strength of this study, the analysis of additional B27-positive healthy subjects further increases the validity of this study. Our original cohort included samples from only 10 B27-positive healthy subjects, but in a second phase we compared these initial results to an independent, previously published cohort of 587 healthy subjects that included 42 B27-positive subjects (20) . This allowed us to assess whether individual motifs are specific to the disease, and suggested that some of the motifs identified are disease-associated and do not result from the HLA genotype of the subjects.
Another strength of this work involves the specimen source that was studied. TCRb repertoire analysis was conducted on blood samples obtained from AS cases and controls. Previous studies have used synovial fluid, and future studies using this next-generation sequencing approach will benefit from analysis of further synovial fluid samples. However, this comprehensive TCRb repertoire analysis of blood samples suggests that our next-generation sequencing approach has broad applicability across sample types, which will be useful for both research and future clinical applications.
The approach we selected likely leads to the identification of motifs with antigen specificity that is mainly driven by TCRb, with lower contribution from the TCRa chain. Future studies assessing both TCRb and TCRa antigen specificity may provide a more comprehensive assessment of HLA-B27-specific binding signatures in AS patients. Indeed, while the majority of motifs were observed in CD81 T cells, the observation of some cases in CD82 (presumptively CD41) T cells suggests that sequences outside the motif in the TCRb and/or the TCRa sequence contribute to the antigen specificity of these motifs. Alternatively, the same TCRb could be binding the same antigen in the context of MHC class I and MHC class II.
In conclusion, we have demonstrated the utility of a next-generation sequencing-based approach to the identification of a set of motifs specific to HLA-B27-positive AS patients. The identification of TCRb sequences specific to AS provides evidence of the presence of specific antigens important in the pathogenesis of AS, and can aid in their identification. This approach can be applied more generally to identify diseaserelated motifs in other diseases, thus providing a new paradigm for studying autoimmune diseases through the identification of shared T cells without a priori knowledge of the relevant antigen.
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